Longfeng Zhao

Real‐world treatment patterns and clinical outcomes of HCV treatment‐naive patients in China: an interim analysis from the CCgenos study

Mei-Hsuan Lee, J. Niu, Lai Wei, 2017, Journal of gastroenterology and hepatology.

aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis.

M. Buti, T. Berg, P. Hayes, 2020, Journal of hepatology.

Heme oxygenase-1 exerts pro-apoptotic effects on hepatic stellate cells in vitro through regulation of nuclear factor-κB

Xiaoqian Zhang, Zhongfu Zhao, Longfeng Zhao, 2018, Experimental and therapeutic medicine.

Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection

Jian Sun, Q. Ning, J. Niu, 2014, Journal of gastroenterology and hepatology.

The effect and mechanism of miR196a in HepG2 cell.

Junping Wang, Longfeng Zhao, Yuxia Hao, 2015, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Heme Oxygenase-1 Inhibits the Proliferation of Hepatic Stellate Cells by Activating PPARγ and Suppressing NF-κB

H. Yang, Xiaoqian Zhang, Zhongfu Zhao, 2022, Comput. Math. Methods Medicine.

Real-World Clinical Outcomes among Individuals with Chronic HCV Infection in China: CCgenos Study

J. Niu, Lai Wei, Jianning Jiang, 2019, Antiviral therapy.

Identifiable biomarker and treatment development using HIV-1 long term non-progressor sera

C. Cao, Jianfeng Cai, Junping Wang, 2015, BMC Immunology.

HOXD 10 acts as a tumor suppressor in hepatocellular carcinoma

Enwei Xu, Wei Zhou, Longfeng Zhao, 2017 .